Orchard Therapeutics CEO Bobby Gaspar, M.D., Ph.D., Appointed to the Alliance for Regenerative Medicine’s 2021 Board of Directors
Orchard Therapeutics (Nasdaq: ORTX) announced that CEO Bobby Gaspar has been appointed to the Alliance for Regenerative Medicine's 2021 board of directors. This role will see Dr. Gaspar guiding ARM's strategic priorities at a crucial time for cell and gene therapies. He emphasized the importance of collaboration to address the challenges posed by transitioning to one-time, potentially curative treatments. ARM is a leading organization advocating for the cell and gene therapy sector worldwide, promoting initiatives that advance patient access to innovative therapies.
- Bobby Gaspar's appointment to ARM's board enhances Orchard's visibility within the gene therapy sector.
- The collaboration with industry peers could foster new opportunities for Orchard's gene therapies.
- Concerns about continuity in leadership roles may arise from Dr. Gaspar's additional responsibilities.
BOSTON and LONDON, Oct. 22, 2020 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today announced that the company’s chief executive officer, Bobby Gaspar, M.D., Ph.D., has been appointed to the Alliance for Regenerative Medicine’s (ARM) 2021 board of directors. In collaboration with the executive committee and board of directors, Dr. Gaspar will provide guidance supporting formation and implementation of ARM’s strategic priorities and focus areas over the coming year.
“I am honored to join the Alliance for Regenerative Medicine’s board at this pivotal time for cell and gene therapies,” said Bobby Gaspar, CEO of Orchard. “As more one-time, potentially curative medicines move toward commercialization, it’s imperative that we work together to meet the needs and challenges of a society accustomed to using chronic therapies to treat diseases. I look forward to collaborating with industry peers toward our common goal of bringing innovative treatment options to patients and families.”
ARM is the leading international multi-stakeholder advocacy organization for the cell and gene therapy sector, promoting legislative, regulatory, and reimbursement initiatives to facilitate access to life-giving advances in regenerative medicine worldwide.
“We are pleased to welcome Bobby Gaspar as one of the accomplished executives joining the 2021 ARM board of directors,” said Janet Lambert, CEO of ARM. “As scientists, commercial leaders, and regulatory experts, the new members of the board will be instrumental in helping ARM and its members deliver transformative and potentially curative cell and gene therapies to patients around the world.”
About Orchard
Orchard Therapeutics is a global gene therapy leader dedicated to transforming the lives of people affected by rare diseases through the development of innovative, potentially curative gene therapies. Our ex vivo autologous gene therapy approach harnesses the power of genetically modified blood stem cells and seeks to correct the underlying cause of disease in a single administration. In 2018, Orchard acquired GSK’s rare disease gene therapy portfolio, which originated from a pioneering collaboration between GSK and the San Raffaele Telethon Institute for Gene Therapy in Milan, Italy. Orchard now has one of the deepest and most advanced gene therapy product candidate pipelines in the industry spanning multiple therapeutic areas where the disease burden on children, families and caregivers is immense and current treatment options are limited or do not exist.
Orchard has its global headquarters in London and U.S. headquarters in Boston. For more information, please visit www.orchard-tx.com, and follow us on Twitter and LinkedIn.
Availability of Other Information About Orchard
Investors and others should note that Orchard communicates with its investors and the public using the company website (www.orchard-tx.com), the investor relations website (ir.orchard-tx.com), and on social media (Twitter and LinkedIn), including but not limited to investor presentations and investor fact sheets, U.S. Securities and Exchange Commission filings, press releases, public conference calls and webcasts. The information that Orchard posts on these channels and websites could be deemed to be material information. As a result, Orchard encourages investors, the media, and others interested in Orchard to review the information that is posted on these channels, including the investor relations website, on a regular basis. This list of channels may be updated from time to time on Orchard’s investor relations website and may include additional social media channels. The contents of Orchard’s website or these channels, or any other website that may be accessed from its website or these channels, shall not be deemed incorporated by reference in any filing under the Securities Act of 1933.
Forward-Looking Statements
This press release contains certain forward-looking statements about Orchard’s strategy, future plans and prospects, which are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include express or implied statements relating to, among other things, Orchard’s business strategy and goals, and the therapeutic potential of Orchard’s product candidates, including the product candidate or candidates referred to in this release. These statements are neither promises nor guarantees and are subject to a variety of risks and uncertainties, many of which are beyond Orchard’s control, which could cause actual results to differ materially from those contemplated in these forward-looking statements. In particular, these risks and uncertainties include, without limitation: the severity of the impact of the COVID-19 pandemic on Orchard’s business, including on clinical development and commercial programs; the risk that any one or more of Orchard’s product candidates, including the product candidate or candidates referred to in this release, will not be approved, successfully developed or commercialized; the risk of cessation or delay of any of Orchard’s ongoing or planned clinical trials; the risk that Orchard may not successfully recruit or enroll a sufficient number of patients for its clinical trials; the risk that prior results, such as signals of safety, activity or durability of effect, observed from preclinical studies or clinical trials will not be replicated or will not continue in ongoing or future studies or trials involving Orchard’s product candidates; the delay of any of Orchard’s regulatory submissions; the failure to obtain marketing approval from the applicable regulatory authorities for any of Orchard’s product candidates or the receipt of restricted marketing approvals; and the risk of delays in Orchard’s ability to commercialize its product candidates, if approved. Given these uncertainties, the reader is advised not to place any undue reliance on such forward-looking statements.
Other risks and uncertainties faced by Orchard include those identified under the heading "Risk Factors" in Orchard’s quarterly report on Form 10-Q for the quarter ended June 30, 2020, as filed with the U.S. Securities and Exchange Commission (SEC), as well as subsequent filings and reports filed with the SEC. The forward-looking statements contained in this press release reflect Orchard’s views as of the date hereof, and Orchard does not assume and specifically disclaims any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required by law.
Contacts
Investors
Renee Leck
Director, Investor Relations
+1 862-242-0764
Renee.Leck@orchard-tx.com
Media
Molly Cameron
Manager, Corporate Communications
+1 978-339-3378
media@orchard-tx.com
FAQ
What position has Bobby Gaspar been appointed to?
What is the significance of Dr. Gaspar's appointment for Orchard Therapeutics?
How does ARM support the gene therapy industry?
What are the potential impacts of Dr. Gaspar's new role on Orchard's operations?
